These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15533054)

  • 1. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
    Hanlon MH; Porter DJ; Furfine ES; Spaltenstein A; Carter HL; Danger D; Shu AY; Kaldor IW; Miller JF; Samano VA
    Biochemistry; 2004 Nov; 43(45):14500-7. PubMed ID: 15533054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
    Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
    FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
    J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
    Maschera B; Darby G; Palú G; Wright LL; Tisdale M; Myers R; Blair ED; Furfine ES
    J Biol Chem; 1996 Dec; 271(52):33231-5. PubMed ID: 8969180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
    Ermolieff J; Lin X; Tang J
    Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.
    Markgren PO; Lindgren MT; Gertow K; Karlsson R; Hämäläinen M; Danielson UH
    Anal Biochem; 2001 Apr; 291(2):207-18. PubMed ID: 11401294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
    Kovalevsky AY; Ghosh AK; Weber IT
    J Med Chem; 2008 Oct; 51(20):6599-603. PubMed ID: 18808097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.
    Markgren PO; Hämäläinen M; Danielson UH
    Anal Biochem; 2000 Mar; 279(1):71-8. PubMed ID: 10683232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
    Todd MJ; Luque I; Velázquez-Campoy A; Freire E
    Biochemistry; 2000 Oct; 39(39):11876-83. PubMed ID: 11009599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
    Miller JF; Andrews CW; Brieger M; Furfine ES; Hale MR; Hanlon MH; Hazen RJ; Kaldor I; McLean EW; Reynolds D; Sammond DM; Spaltenstein A; Tung R; Turner EM; Xu RX; Sherrill RG
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1788-94. PubMed ID: 16458505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
    Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
    J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.